Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents

Guishui Zhang1, Crispin R Dass, Eric Sumithran

  • 1Centre for Vascular Research, The University of New South Wales and Department of Haematology, The Prince of Wales Hospital, Sydney, Australia.

Abstract

Insights

DNAzymes targeting c-Jun inhibit angiogenesis and tumor growth. This study demonstrates the therapeutic potential of Dz13 in blocking endothelial cell functions and reducing neovascularization and tumor size.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Vascular Biology

Background:

  • The transcription factor c-Jun is implicated in cell proliferation, transformation, and apoptosis.
  • A direct role for c-Jun in angiogenesis has not been established.

Purpose of the Study:

  • To investigate the role of c-Jun in angiogenesis.
  • To evaluate the therapeutic potential of targeting c-Jun using DNAzymes.

Main Methods:

  • Human microvascular endothelial cells (HMEC-1) were transfected with a c-Jun targeting DNAzyme (Dz13).
  • In vitro assays assessed endothelial cell proliferation, migration, chemoinvasion, and tubule formation.
  • In vivo studies utilized rat corneal neovascularization and mouse solid tumor models.

Main Results:

  • Dz13 transfection reduced c-Jun protein levels and DNA-binding activity in HMEC-1 cells.
  • Dz13 inhibited endothelial cell proliferation, migration, chemoinvasion, and tubule formation.
  • Dz13 significantly reduced VEGF-induced corneal neovascularization and suppressed solid melanoma growth and vascular density in mice.

Conclusions:

  • Targeting c-Jun with DNAzymes inhibits key processes of angiogenesis.
  • DNAzymes targeting c-Jun demonstrate therapeutic potential for inhibiting tumor angiogenesis and growth.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...